Evidence map›Paper›PMID 25715867›Full record

ArticleClinical and experimental nephrology2015

Growth impairment in children with pre-dialysis chronic kidney disease in Japan.

Yuko Hamasaki, Kenji Ishikura, Osamu Uemura, Shuichi Ito, Naohiro Wada, Motoshi Hattori, Yasuo Ohashi, Ryojiro Tanaka, Koichi Nakanishi, Tetsuji Kaneko and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical and experimental nephrology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Yuko HamasakiDepartment of Pediatric Nephrology, Toho University Faculty of Medicine, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan. yuhamasaki@med.toho-u.ac.jp.
Kenji IshikuraDepartment of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Osamu UemuraDepartment of Pediatric Nephrology, Aichi Children's Health and Medical Center, Aichi, Japan.
Shuichi ItoDepartment of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama, Japan.
Naohiro WadaDepartment of Pediatric Nephrology, Shizuoka Children's Hospital, Shizuoka, Japan.
Motoshi HattoriDepartment of Pediatric Nephrology, Tokyo Women's Medical University, Tokyo, Japan.
Yasuo OhashiDepartment of Integrated Science and Technology for Sustainable Society, Chuo University, Tokyo, Japan.
Ryojiro TanakaDepartment of Nephrology, Hyogo Prefectural Children's Hospital, Hyogo, Japan.
Koichi NakanishiDepartment of Pediatrics, Wakayama Medical University, Wakayama, Japan.
Tetsuji KanekoDivision of Clinical Research Support Center, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Masataka HondaDepartment of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan.
Tokyo Metropolitan Children's Medical Center · JPChuo University · JPKobe Children's Hospital · JPShizuoka Children's Hospital · JPToho University · JPTokyo Women's Medical University · JPWakayama Medical University · JPYokohama City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGrowth impairment is a major complication of chronic kidney disease (CKD) in children. However, no cohort studies have examined the growth of Asian children with pre-dialysis CKD.

methodsWe sent cross-sectional surveys to 113 Japanese medical institutions that were treating 447 children with CKD stages 3-5 in 2010 and 2011. Of 447 children included in our survey conducted in 2010, height and CKD stage were evaluable for 297 children in 2011, and height standard deviation score (height SDS) was calculated in these children.

resultsHeight SDS decreased with increasing CKD stage (P < 0.001) in boys and girls. Height SDS also decreased significantly with increasing CKD stage among patients with congenital anomalies of the kidney and urinary tract (P < 0.001). Risk factors for growth impairment included CKD stages 4 and 5 (relative to stage 3), being small-for-date, and asphyxia at birth. Among children with a height SDS ≤-2.0, growth hormone was used in 19.5, 31.0, and 25.0 % of children with CKD stages 3, 4, and 5, respectively.

conclusionsThis prospective cohort study revealed marked growth impairment in Japanese children with CKD stages 3-5 relative to healthy children. CKD-related risk factors for growth impairment included advanced CKD (stages 4 and 5), being small-for-date, and asphyxia at birth. Growth hormone was infrequently used in this cohort of children with pre-dialysis CKD.

Indexed as

Asphyxia NeonatorumBody HeightChildCohort StudiesCross-Sectional StudiesDisease ProgressionFemaleGlomerular Filtration RateGrowth DisordersHealth SurveysHumansInfant, NewbornJapanMaleProspective StudiesRenal DialysisChildChronic kidney diseaseGrowthGrowth hormoneJapan

Identifiers

PMID25715867
OpenAlexW2084963540

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.